Baricitinib: From Rheumatoid Arthritis to COVID‐19
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1874
Abstract: Baricitinib is a JAK1/2 inhibitor that was first approved for treating moderate to severe rheumatoid arthritis (RA) but that later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide… read more here.
Keywords: baricitinib; arthritis covid; rheumatoid arthritis; baricitinib rheumatoid ... See more keywords